title: End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia.
abstract: The role of end of induction minimal residual disease (MRD) as determined by flow cytometry for treatment assignment in pediatric T-cell acute lymphoblastic leukemia (T-ALL) is not well defined. We studied 33 children with newly diagnosed T-ALL. Thirty-two of 33 patients remain in continuous complete remission at a median of 4 years. Nineteen patients were MRD positive at the end of induction and all remain in remission with augmented Berlin Frankfurt Münster-based therapy. One patient underwent hematopoietic stem cell transplant for rising MRD. Persistent end of induction MRD alone is not an indication to alter therapy in pediatric T-ALL.
authors.affiliation: Children's Center for Cancer and Blood Disease, Children's Hospital Los Angeles, Los Angeles, California.|Keck School of Medicine, University of Southern California, Los Angeles, California.
authors.forename: Chintan
authors.initials: C
authors.lastname: Parekh
authors.affiliation: Children's Center for Cancer and Blood Disease, Children's Hospital Los Angeles, Los Angeles, California.|Keck School of Medicine, University of Southern California, Los Angeles, California.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Gaynon
authors.affiliation: Children's Center for Cancer and Blood Disease, Children's Hospital Los Angeles, Los Angeles, California.|Keck School of Medicine, University of Southern California, Los Angeles, California.
authors.forename: Hisham
authors.initials: H
authors.lastname: Abdel-Azim
mesh_terms: D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D018365:Neoplasm, Residual; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000628:therapy*; D012074:Remission Induction; D018570:Risk Assessment
keywords: T-ALL; minimal residual disease; pediatric